LC said Her-Vaxx has shown greater safety signal. It has the same or potential better efficacy.
The other company product makes 7-8B. It has been approved for a long time.
Imugene has a easier runway of what to do Next: Further studies or Discussion with regulator.
Note: Her-Vaxx is a study to treat Gastric Cancer.
Gastric Cancer is mostly common to Asian people.
Imugene's Leslie Chong says positive HER-Vaxx data 'validates entire platform'
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
-0.001(1.41%) |
Mkt cap ! $512.3M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.1¢ | 6.8¢ | $922.0K | 13.28M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 702419 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.1¢ | 1365317 | 9 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.0¢ |
Change
-0.001 ( 1.69 %) |
||||
| Open | High | Low | Volume | ||
| 7.0¢ | 7.1¢ | 6.8¢ | 5455105 | ||
| Last updated 15.59pm 24/05/2024 ? | |||||
| IMU (ASX) Chart |